Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 18223: A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed o

99 years and younger
All genders
This is a phase 1 first in human, dose escalation trial in subjects with advanced pancreatic cancer previously treated with 5-Fluorouacil-based Chemotherapy but never exposed to therapeutic gemcitabine.
Learn More

UPCC 24423: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

99 years and younger
All genders
Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints). Please refer to Protocol Section 3.0 (Objectives and Endpoints).
Learn More

UPCC 43422: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

99 years and younger
All genders
Please refer to Protocol 17-054, Section 2.0 (Objectives and Scientific Aims) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Primary Endpoints) Please refer to Protocol 17-054, Section 14.0 (Biostatistics, Secondary Endpoints)
Learn More

UPCC 49422: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

99 years and younger
All genders
Please refer to Protocol, Section 2.0 (Objectives) Please refer to Protocol, Section 4.0 (Study Endpoints) Please refer to Protocol, Section 4.0 (Study Endpoints)
Learn More

UPCC 19223 Open-Label Dose-Finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients with Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroeso

99 years and younger
All genders
Please refer to Protocol Section 2.1.1 (Main objectives). Please refer to Protocol Section 2.1.2 (Primary endpoint(s). Please refer to Protocol Section 2.1.4 (Secondary endpoints).
Learn More

NRG-GI008: Colon Adjuvent Chemotherapy Based on Evaluation of Residual Disease (Circulate-US)

99 years and younger
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal cancer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Learn More

UPCC 28423: Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab i

99 years and younger
All genders
This is a Phase 1/2a, dose-escalation, multicenter, first-in-human, consecutive-cohort, open-label study of BI-1808, as a single agent and in combination with pembrolizumab in subjects with advanced malignancies, whose disease has progressed after standard therapy. We would like to rely on WCG as the IRB of record for this study.
Learn More

EA8153: Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial

99 years and younger
All genders
We would like to rely on the NCI CIRB as the IRB of record for this study. The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone based therapy …
Learn More

UPCC 19222: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC

99 years and younger
All genders
To evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with bevacizumab and FOLFIRI (5-fluorouracil [5-FU], irinotecan, and leucovorin [LV]) in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC). We would like to rely on Advarra as the IRB of record for this …
Learn More

UPCC 30423: A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non- Hodgkin Lymphoma

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
81 - 90 of 206